跳至主要内容
临床试验/JPRN-jRCT1030210419
JPRN-jRCT1030210419尚未招募未知

Study on the effect of disease modifiers on pain, fatigue and quality of life (QOL) in patients with neuromyelitis optica spectrum disorder (NMOSD)

Kazuhiro Ishii0 个研究点目标入组 30 人开始时间: 2021年11月10日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • The NMOSD diagnosis follows the diagnostic criteria of Wingerchuk et al. (Wingerchuk DM 2007, 2015). The subjects were patients who were diagnosed, treated, or newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD) at our hospital from September 2020 to March 31, 2022. Patients who started administration of oral steroid humanized monoclonal antibody (Satralizumab, etc.) as a therapeutic intervention.

排除标准

  • Minors (under 20 years old)

研究者

发起方
Kazuhiro Ishii

相似试验